Business Strategy Sterling Pharma Solutions Invests 1-Million-Dollars for Expanding UK Site

Source: Press release

Sterling Pharma Solutions has plans to expand its bioconjugation and antibody-drug conjugates (ADCs) facility in Deeside, the UK. The hefty investment is in line with the company’s strategy to support the growth of its ADC capabilities.

Related Companies

The project will increase the current laboratory space from 275 to 419 square meters, and reconfigure the layout to provide the ability to develop and expand areas in the future for additional services.
The project will increase the current laboratory space from 275 to 419 square meters, and reconfigure the layout to provide the ability to develop and expand areas in the future for additional services.
(Source: Sterling Pharma Solutions)

Cramlington/UK – Sterling Pharma Solutions has recently announced a 1.31-million-dollar expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters, and reconfigure the layout to provide the ability to develop and expand areas in the future for additional services.

This investment is part of a strategy to support the growth of the company’s ADC capabilities since it acquired the 6,500 square-metre site in April 2021, to expand and develop the facility’s scientific and analytical teams, and establish Cgmp bioconjugation/ADC manufacturing capabilities. The work and expansion will allow the recruitment of up to five additional scientists at the facility.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

A new mass spectrometer has been installed at the site’s process development laboratory, and in addition to serving Sterling’s ADC business, will provide support for the company’s range of customer analytical services, working in both ADC and small molecule development. The instrument is located in a controlled environment with temperature controls, airlocks, and Hepa filters, allowing the safe handling and analysis of cytotoxic and highly potent materials.

“Having the capabilities to develop ADC bioconjugation methods and scale up through to GMP manufacture in the same location has been one of Sterling’s major priorities since the acquisition of the Deeside facility, enabling projects to progress through development phases without needing relocation or tech transfer,” commented Stewart Mitchell, Sterling’s Deeside Site Head. “We are currently integrating the site’s quality management systems in line with our global practices and are now commissioning the QC and manufacturing facilities in readiness for GMP certification, which we anticipate will be in place by late 2022.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:48205603)